Antibody binding to carbonic anhydrase and use thereof
Provided is an antibody that recognizes and binds to carbonic anhydrase or antigen-binding fragment, a nucleic acid molecule coding for the antibody or antigen-binding fragment, a vector carrying the nucleic acid molecule, a host cell including the nucleic acid molecule or the vector, and use of the antibody or antigen-binding fragment thereof in the alleviation, prevention, treatment or diagnosis of solid cancers.
1. An antibody or an antigen-binding fragment thereof, binding to carbonic anhydrase, wherein the antibody or an antigen-binding fragment thereof comprises a CDR-H1 comprising SEQ ID No: 6, a CDR-H2 comprising SEQ ID No: 7, a CDR-H3 comprising SEQ ID No: 8, a CDR-L1 comprising SEQ ID No: 9, a CDR-L2 comprising SEQ ID No: 10, and a CDR-L3 comprising SEQ ID No: 11.
2. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment thereof binds to an epitope which is a peptide consisting of 7 to 93 consecutive amino acids containing the amino acid sequence of SEQ ID NO: 1 among amino acid sequence of SEQ ID NO: 5.
3. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment thereof binds to an epitope which is a peptide consisting of 14 to 93 consecutive amino acids containing the amino acid sequence of SEQ ID NO: 2 among amino acid sequence of SEQ ID NO: 5.
4. The antibody or antigen-binding fragment thereof according to claim 3 , wherein the antibody or antigen-binding fragment thereof binds to an epitope which is a peptide consisting of 7 to 14 consecutive amino acids containing the amino acid sequence of SEQ ID NO: 1 among amino acid sequence of SEQ ID NO: 2.
5. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment thereof binds to an epitope which is a peptide consisting of 7 to 93 consecutive amino acids containing the amino acid sequence of SEQ ID NOs: 1, or 2.
6. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody comprises amino acid sequences comprising amino acids of SEQ ID No: 12 of V H and amino acid sequences comprising amino acids of SEQ ID No: 13 of V L .
7. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or the antigen-binding fragment thereof is coupled to labeling agents, toxins, or anti-tumor drugs.
8. The antibody or antigen-binding fragment thereof according to claim 7 , wherein the labeling agent is selected from the group consisting of a radioisotope, a hapten or a fluorescent, a chromogen, and a dye.
9. The antibody or antigen-binding fragment thereof according to claim 7 , wherein the toxin is selected from the group consisting of a radioisotope, a small molecule, a peptide, and a protein.
10. The antibody or antigen-binding fragment thereof according to claim 7 , wherein the antibody or antigen-binding fragment thereof is coupled with a toxin to form a fusion protein.
11. A pharmaceutical composition, comprising the antibody or antigen-binding fragment thereof that binds to carbonic anhydrase according to claim 1 .
12. The pharmaceutical composition according to claim 11 , wherein the antibody or antigen-binding fragment thereof is coupled to a toxin.
13. The pharmaceutical composition according to claim 11 , further comprising an anti-cancer agent.
14. A composition for detecting a solid cancer that comprises the antibody or antigen-binding fragment thereof according to claim 1 , wherein the solid cancer is breast cancer, lung cancer, colorectal cancer, stomach cancer, prostate cancer, and liver cancer.
15. The composition for detecting a solid cancer according to claim 14 , wherein the antibody or the antigen-binding fragment thereof is coupled to labeling agents.